Magadh Chronicle

Diabetic Kidney Disease Clinical Trials | A Drug Pipeline Analysis Report 2022 | DelveInsight

 Breaking News
  • No posts were found

Diabetic Kidney Disease Clinical Trials | A Drug Pipeline Analysis Report 2022 | DelveInsight

January 23
18:17 2023
Diabetic Kidney Disease Clinical Trials | A Drug Pipeline Analysis Report 2022 | DelveInsight
Diabetic Kidney Disease Pipeline Insights
United States, Nevada, Las Vegas, DelveInsight’s ‘Diabetic Kidney Disease Pipeline Insight 2022’ report provides comprehensive global coverage of available, marketed, and pipeline Diabetic Kidney Disease therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Diabetic Kidney Disease pipeline domain.

United States, Nevada, Las Vegas, DelveInsight’s Diabetic Kidney Disease Pipeline Insight 2022 report provides comprehensive global coverage of available, marketed, and pipeline Diabetic Kidney Disease therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Diabetic Kidney Disease pipeline domain.

Key Takeaways from the Diabetic Kidney Disease Pipeline Report

  • Leading Diabetic Kidney Disease companies developing novel drug candidates to improve the Diabetic Kidney Disease treatment landscape include Bayer, Gilead Sciences, Kyowa Kirin, Dimerix, and others.
  • Promising Diabetic Kidney Disease pipeline therapies in various stages of development include Finerenone (BAY94–8862), Selonsertib (SEL), Bardoxolone methyl, DMX-200, and others.

Diabetic Kidney Disease Overview

Diabetic Kidney Disease is a type of kidney disease caused by diabetes, when high blood glucose initiate to damage the blood vessels in kidneys and creates problem in its functioning. Diabetic kidney disease is also called as chronic kidney disease, CKD, kidney disease of diabetes, or diabetic nephropathy.

DKD generally results due to high blood glucose that can damage the blood vessels in the kidneys, which thereby results into high blood pressure that can damage the kidneys further. The basic symptoms of DKD are swelling of the hands, feet, and face, trouble sleeping or concentrating, poor appetite, nausea, weakness, itching (end-stage kidney disease) and extremely dry skin, drowsiness (end-stage kidney disease), abnormalities in the hearts’ regular rhythm because of increased potassium in the blood, muscle twitching etc.

Diabetic Kidney Disease Pipeline Analysis: Drug Profile

Finerenone (BAY94–8862) by Bayer, which is a nonsteroidal mineralocorticoid receptor antagonist in development for the treatment of diabetic kidney disease. It blocks the detrimental effects due to over activation of the receptor by aldosterone and cortisol, which increases blood pressure and has been implicated in a number of other deleterious effects in the kidney, vasculature, and heart. While aldosterone secretion is inhibited by angiotensin– converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs). Currently, the drug is in phase III stage of clinical development for DKD.

Discover more about the emerging Diabetic Kidney Disease drugs @ Diabetic Kidney Disease Treatment Drugs

Diabetic Kidney Disease Key Companies

  • Bayer
  • Gilead Sciences
  • Kyowa Kirin
  • Dimerix

Diabetic Kidney Disease Pipeline Therapies

  • Finerenone (BAY94–8862)
  • Selonsertib (SEL)
  • Bardoxolone methyl
  • DMX-200

Diabetic Kidney Disease Pipeline Therapeutics Assessment

  • By development stage
  • By product type
  • By route of administration
  • By molecule type
  • By MOA type 

Scope of the Diabetic Kidney Disease Pipeline Report 

  • Coverage: Global 
  • Key Diabetic Kidney Disease Companies: Bayer, Gilead Sciences, Kyowa Kirin, Dimerix, and others
  • Key Diabetic Kidney Disease Pipeline Therapies: Finerenone (BAY94–8862), Selonsertib (SEL), Bardoxolone methyl, DMX-200, and others

Find out more about the Diabetic Kidney Disease treatment options in development @ Diabetic Kidney Disease Clinical Trials

Table of Contents

1. Introduction

2. Executive Summary

3. Overview

4. Pipeline Therapeutics

5. Late-Stage Products (Phase III)

6. Mid-Stage Products (Phase  II)

7. Early Stage Products (Phase  I/II)

8. Preclinical Stage Products

9. Discovery Stage Products

10. Therapeutic Assessment

11. Inactive Products

12. Collaborations Assessment- Licensing / Partnering / Funding

13. Unmet Needs

14. Market Drivers and Barriers

15. Appendix

16. About DelveInsight

Request for a sample report to know more about the leading companies in the diabetic kidney disease pipeline domain.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/